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SUBSTITUTION FLUIDS FOR CRRT
Lactate- or bicarbonate-buffered solutions in continuous
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Lactate- or bicarbonate-buffered solutions in continuous extra- [1]. However, blood pressure-dependent filtration could
corporeal renal replacement therapies. not adequately control azotemia in hemodynamically un-
Background. Continuous renal replacement therapies stable patients with ARF. Therefore, a number of treat-(CRRTs) are well accepted for critically ill patients with acute
ment methods aimed at combining the advantages of con-renal failure (ARF). Today, daily fluid exchange in CRRT
tinuous therapy with a higher effectiveness have beenreaches 30 to 40 liter and more. Therefore, the composition
of the substitution/dialysate fluid, often primarily developed developed since the beginning of the eighties [2, 3]. Their
either for intermittent treatment or for peritoneal dialysis, be- common feature, for instance continuous arteriovenous
comes more relevant. Lactate (30 to 45 mmol/liter) is frequently
hemodialysis and pump-assisted venovenous methodsused as the buffer because of the high stability of this substance.
such as continuous venovenous hemofiltration (CVVH)However, lactate is thought to have negative effects on meta-
bolic and hemodynamic parameters. or continuous venovenous hemodialysis (CVVHD), is
Methods. Published data for different substitution fluids are that their greater efficacy enables them to satisfactorily
presented with respect to acidosis and lactate concentration, maintain even hemodynamically unstable hypercatabolic
uremia, and hemodynamic and metabolic alterations.
patients with ARF and multiple organ dysfunction syn-Results. Only a few studies compare substitution fluids with
drome (MODS) [3]. In contrast to CAVH in these formsdifferent buffers. Uremia and acidosis (pH, base excess) were
sufficiently controlled during CRRT with an exchange volume of treatment, daily fluid exchange reaches 30 to 40 liters
of in average 30 liters using either buffer. If patients with severe and more, so that the composition of the substitution
liver failure and lactic acidosis were excluded, no difference in fluid becomes more relevant than in the early low-volumehemodynamic and metabolic parameters between the solutions
CAVH method.occurred. The plasma lactate concentration was elevated dur-
ing lactate use in some cases, but lactate levels remained within
normal limits in patients without liver impairment. The bicar-
SOLUTIONS FOR FLUID REPLACEMENT:bonate concentration in the solutions should exceed 35 to 40
mmol/liter, as in some cases the buffer capacity of the solutions IMPORTANCE OF BUFFER
was inadequate. In patients with severe liver failure or lactic
Renal replacement therapy in ARF has three majoracidosis, solutions with lactate buffer were shown not to be
aims [4]: detoxification, fluid elimination, and compensa-indicated.
Conclusion. In patients with reduced lactate metabolism, for tion of acidosis. In CRRT, the physical properties of
example, concomitant severe liver failure, after liver trans- hemofiltration, hemodialysis, or hemodiafiltration tech-
plantation or in lactic acidosis, bicarbonate-buffered solutions niques are therefore used. In continuous treatment formsshould be used. In nearly all other cases of critically ill patients
exclusively using hemofiltration, the ultrafiltrate is com-with ARF, lactate-buffered solutions may be used as well as
pletely replaced by a sterile substitute solution. For suf-bicarbonate solutions.
ficient control of azotemia also in MODS patients,
CVVH treatment minimally requires a total of about 30
Many efforts have been made to reduce the high mor- liters of hemofiltrate per day [5]. In techniques using
tality of patients with acute renal failure (ARF). One of hemodialysis, a defined quantity of dialysate passes on
these is the development of continuous renal replacement the outer side of the dialyzator as in intermittent hemodi-
therapies (CCRTs). CRRT, first published in 1977 by alysis. A certain quantity of ultrafiltrate is still produced
Kramer et al as continuous arteriovenous hemofiltration so that the therapy represents a combination of dialysis
(CAVH), quickly gained ground because of its simplicity and filtration, that is, of diffusive and convective trans-
port [6]. For an effective treatment, a dialysate flow rate
of 1 to 2 liters/hr (24 to 48 liters/day) is needed.Key words: acute renal failure, continuous renal replacement therapy,
dialysate, acidosis. Substitution fluids and dialysate used in CRRT have
been primarily developed for intermittent hemofiltration 1999 by the International Society of Nephrology
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or peritoneal dialysis. In CRRT techniques also including by CRRT using either bicarbonate- or lactate-buffered
solutions. We could show that within 48 hours, uremiadialysis, any ready-to-use dialysis solution may be em-
ployed. In nearly all commercially available fluids, lac- was well controlled using either buffer with a daily ex-
change volume of 30 liters and more, in accordance withtate (30 to 45 mmol/liter), which is converted to bicarbon-
ate on an equimolar basis under physiological conditions, data of other groups using lactate-buffered substitution
solutions [14, 15, 19].is used as the buffer to correct acidosis. The lactate buffer
has the advantage of greater stability over a physiological
bicarbonate buffer. However, lactate is thought to have HEMODYNAMIC PARAMETERS
negative effects on hemodynamic parameters [7] and on
Especially acetate, but also lactate buffer, has beenmetabolic parameters, for example, enhanced protein
shown to exert a negative influence on the mean arterialcatabolism and decreased regeneration rate of adenosine
blood pressure and cardiac function in the critically ill59-triphosphate (ATP) because of the fact that conver-
[7, 18, 20]. Acetate-buffered substitution fluids shouldsion from lactate to bicarbonate needs energy [8]. Lac-
be avoided, as a significantly reduced control of acidosistate-buffered substitution solutions or dialysate according
compared with a lactate-buffered solution has been re-to the daily fluid exchange may lead to a daily lactate
cently reported during CVVH [21]. We investigated theload of 800 to 1300 mmol. Case reports of a reduced
influence of a lactate- and a bicarbonate-buffered substi-lactate tolerance and a tendency to develop hyperlacta-
tution solution on hemodynamic and other parameterstemia during treatment with lactate-buffered solutions
in patients with ARF and MODS who were undergoingalso exist [9]. ARF patients with concomitant severe liver
CVVH in a crossover designed study [15]. The composi-failure or hemodynamic instability in particular display
tion of the solutions used in that study is given in Table 1.an increased plasma lactate level as the conversion of
There was no difference in hemodynamic parameters mea-lactate into bicarbonate is diminished [10]. There is some
sured as mean arterial blood pressure (75.5 6 24.0 mm Hgtheoretical evidence that metabolic and hemodynamic
for all patients) and blood pressure drop of more thandisadvantages of lactate buffering can be avoided by the
30%, or in the need of positive inotropic substances be-use of bicarbonate-buffered solutions. These solutions
tween the groups with different buffers. During hyperlac-had been reported as early as 1985 as an alternative
tatemia (lactate . 5 mmol/liter), a reduced myocardialreplacement fluid for CAVH [11].
performance [20] caused by an increased intracellular lac-
tate concentration, leading to reduced cellular ATP pro-
CLINICAL EXPERIENCE WITH SOLUTIONS duction, has been reported. A correlation of mean arterial
USED IN CRRT blood pressure to the degree of lactate intolerance has
also been described [20]. In contrast to these data andTo date only a few studies have compared different
buffers used in substitution fluids. From these data, there pathophysiological reflections in our own study and some
recently published articles (abstract; McLean et al, J Amseems to be no controversy that acetate-buffered substi-
tution fluids should be avoided, as a significantly reduced Soc Nephrol 9:1413, 1996) [16], there was no negative
influence of lactate buffer. The hemodynamic status ofcontrol of acidosis compared with a lactate-buffered so-
lution has been recently reported during CVVH [7], and the patients was comparable using either bicarbonate-
or lactate-buffered solutions. In our own experience, thislower hemodynamic stability is described in CRRT and
intermittent dialysis procedures [10, 12, 13]. Solutions blood pressure stability is probably due to the fact that in
these patients, despite significantly higher lactate levelsused in peritoneal dialysis have also been recommended
as an alternative [2, 11, 14], but their high glucose concen- during the substitution with lactate buffer, lactate levels
never left the normal limits [15]. These findings had beentration can lead to incomplete metabolism, requiring
additional insulin with concomitant metabolic alterations impressively confirmed in the work of Thomas et al, who
could show no differences in terms of cardiac index, leftin MODS patients.
Some studies dealt with bicarbonate-buffered solu- venticular stroke work index, and oxygen consumption
for different buffers by right heart catheter measure-tions compared with lactate-buffered solutions. Major
goals in these studies have been control of uremia, con- ments [16].
trol of acidosis and lactate concentration, metabolic
changes, hemodynamic parameters, and the concentra- LACTATE CONCENTRATION
tion of the important serum.
Hyperlactatemia has been reported during lactate-buf-
fered substitution in critically ill patients with ARF ad-
CONTROL OF UREMIA AND ministered in intermittent hemofiltration with a lactate
GENERAL ACCEPTANCE load of 190 to 210 mmol/hr [7]. In contrast, patients in
CRRT receive a maximum lactate load of 90 to 100Bicarbonate-buffered solutions have been shown to
be very well tolerated by MODS patients [14–18]. All mmol/hr, even when fluid exchange in filtration or dialy-
sate techniques increases to 2 liters/hr. The slower ultra-critically ill patients with ARF were effectively treated
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Table 1. Composition of a lactate-buffered and two different bicarbonate-buffered solutions for CRRT
Lactate-buffered Bicarbonate- Bicarbonate-
solution buffered solution I buffered solution II
Sodium mmol/liter 142 140 142
Chloride mmol/liter 103 110 104.5
Calcium mmol/liter 2.0 1.75 1.75
Potassium mmol/liter 0 0 0
Magnesium mmol/liter 0.75 0.5 0.5
Glucose mmol/liter 5.6 5.6 5.6
Lactate mmol/liter 44.5 3.0 3.0
Bicarbonate mmol/liter 0 34.5 40
Portions of this table were published in Contributions in Nephrology 116:38–47, 1995 [15]. Used with permission.
filtration in CRRT compared with intermittent hemofil- solution (abstract; McLean et al, ibid). According to the
results of our own study, we composed a bicarbonate-tration may be the reason for the better lactate tolerance
in critically ill patients, despite the same total quantity buffered solution with a higher bicarbonate concentra-
tion (Table 1). Comparing this solution (bicarbonate IIof substituted lactate (1000 to 1200 mmol/day). Lactate
could be an effective bicarbonate generating base in pa- solution) against a lactate-buffered solution, the bicar-
bonate concentration of the patients in this group wastients with acute or chronic renal failure [7, 8]. Under
stable clinical conditions, 2000 mmol of lactate per day significantly increased as compared with the lactate
group and the bicarbonate I group (Table 2). Azotemiaare metabolized to bicarbonate on an equimolar basis.
Critically ill patients with ARF, especially with concomi- was well controlled with this solution, and no difference
according to hemodynamic parameters compared withtant sepsis or circulatory shock, have been reported to
display a reduced lactate tolerance [9]. In our study, the lactate solution occurred.
which excluded patients with liver failure, the only sign
of a possible lactate intolerance was the significantly
METABOLIC PARAMETERS
higher lactate levels during lactate buffering (P 5 0.0018),
Olbricht, Huxmann-Na¨geli, and Bischoff described abut lactate levels never left the normal limits. In addition,
25% lower protein catabolic rate in ARF patients treatedlactate values decreased in both groups compared with
with CAVH using bicarbonate buffer as compared withbaseline levels [15]. These results had been confirmed
historical controls that were substituted with lactateby Thomas et al, who also reported significantly higher
buffer [13]. In our own studies, no differences betweenlactate levels during lactate buffering without any clinical
the groups were found for ammonia and glucose. Nitro-signs of hyperlactatemia [16].
gen excretion differed significantly between the lactate
group and the bicarbonate I group for days 1 through 4
ACIDOSIS (P 5 0.0035), whereas there was no difference when we
compared the bicarbonate II solution with the lactateSufficient control of acidosis was reported by Hilton
et al using a bicarbonate buffer [17]. In our own study, solution (Table 2) [15]. Lactate infusions have been re-
ported to induce a higher degree of protein catabolismthere was no difference in pH or base excess between
the buffer solutions. Astonishingly, the bicarbonate con- than bicarbonate [8]. In our first experience, nitrogen ex-
cretion was significantly increased in patients receivingcentration was significantly higher (P 5 0.035) during the
reception of the lactate-buffered solution compared with lactate-buffer on days 1 through 4 [15], whereas in a second
part of the study on days 5 through 8, there was no signifi-patients receiving the bicarbonate I solution (Table 2)
[15]. The same phenomena occurred in another study [16]. cant difference. This is probably due to the higher protein
catabolic rate in critically ill patients on the first threeWe explained this “mysterium” by the lower quantity of
buffer substances in the bicarbonate-buffered solution to five days [12], but may also be of no or minor relevance
because when we used the bicarbonate II solution with(34.5 mmol/liter bicarbonate and 3 mmol/liter lactate) com-
pared with the lactate-buffered solution (44.5 mmol/liter a higher content of bicarbonate, there was no statistical
difference in nitrogen excretion compared with the lac-lactate). In a recently published study, a bicarbonate-
buffered substitution solution with a higher amount of bi- tate buffer. Protein catabolism may also be due to the
blockade of the conversion of pyruvate to oxaloaceticcarbonate (40 mmol/liter) showed a better control of acido-
sis than a lactate-buffered solution (abstract; McLean et acid, a mechanism that prevents intracellular gluconeo-
genesis [20]. Despite this, we and others could not showal, J Am Soc Nephrol 9:1413, 1996). Additionally, there
was also a clear trend to higher serum bicarbonate con- any difference in carbohydrate metabolism between the
two buffers (Table 2) [15–17, 21].centrations in the group with the bicarbonate-buffered
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Table 2. Acid-base status and metabolic parameters of patients with ARF and MODS during CVVH with lactate-buffered or different
bicarbonate-buffered solutions
Lactate Bicarbonate I Bicarbonate II
pH Before CVVH 7.4360.07 7.38 60.06 7.39 60.10
Day 4 7.43 60.07 7.43 60.03 7.42 60.08
Bicarbonate mmol/liter Before CVVH 23.5 63.9 19.9 64.4 23.6 65.8
Day 4 23.8 62.5 22.5 62.5a 25.563.9a,b
Lactate mmol/liter Before CVVH 2.49 61.04 2.54 62.49 3.50 62.8
Day 4 1.59 61.17 0.76 60.86a 1.961.8b
Nitrogen excretion g/day Before CVVH – – –
Day 4 25.5 610.4 19.3 67.6a 21.669.3
Glucose mmol/liter Before CVVH 10.7 65.1 11.3 66.3 12.9 62.6
Day 4 9.7 62.8 9.7 62.9 11.864.8
Ammonia mmol/liter Before CVVH 44.5 626.2 60.0 640.1 51.1 621.3
Day 4 31.6 616.9 45.2 633.8 41.4 622.1
a P , 0.05 vs. lactate group
b P , 0.05 vs. bicarbonate I group
The composition of each buffer is described in Table 1. Abbreviations are: ARF, acute renal failure; MODS, multiple organ dysfunction syndrome; CVVH,
continuous veno-venous hemofiltration; sd, standard deviation. Some of the data in this table were published in Contributions in Nephrology 116:38–47, 1995 [15],
and are used with permission.
ELECTROLYTES magnesium carbonate, the concentration of these elec-
trolytes is reduced. Additionally, phosphate is not in-Bicarbonate solutions must be stable for a 24-hour
cluded in the solution. The patients’ serum concentrationperiod without precipitation of calcium carbonate or
of these electrolytes must therefore be carefully moni-magnesium carbonate [13]. Therefore, the magnesium
tored, and electrolytes must be added if necessary. Espe-and calcium concentration is reduced compared with the
cially the magnesium concentration in bicarbonate solu-lactate-buffered solution. To adjust ionic strength, the
tions may be insufficient in patients with arrhythmia orchloride concentration must be increased. Possible pre-
depleted cardiac function.cipitation does not allow a higher phosphate concentra-
tion in one of the solutions, and thus, phosphate must
be separately substituted to avoid phosphate depletion, CONCLUSION
as MODS patients with ARF tend to develop hypophos-
In conclusion, in patients with reduced lactate metabo-phatemia leading to decreased respiratory and cardiac
lism, for example, concomitant hepatic failure, after liverfunction. In our study, no differences between the groups
transplantation or lactic acidosis, bicarbonate-bufferedin phosphate, potassium, chloride, or sodium concentra-
solutions should be used as the replacement fluid. Intion occurred. Differences in chloride, calcium, and mag-
nearly all other critically ill patients, the physiologicalnesium were released by the composition of the bicar-
capacity of lactate metabolism allows the use of lactate-bonate buffer determined by the chemical properties of
buffered solutions. Acetate-buffered solutions and solu-the compound [15].
tions containing high amounts of glucose should be
avoided. It must be realized that the bicarbonate solution
PROBLEMS IN DAILY USE OF BICARBONATE- has to be mixed immediately before use from a buffer-
BUFFERED SOLUTIONS free electrolyte solution and the buffer. The administra-
Three major problems may occur in daily use of bicar- tion of the buffer-free electrolyte solution may endanger
bonate-solutions. the patients.
(a) The solution has to be mixed immediately before
Reprint requests to Horst P. Kierdorf, M.D, Department of Internaluse from a buffer-free electrolyte solution and the bicar-
Medicine II, University Clinic Aachen, Pauwelsstreet 30, 52057 Aachen,
bonate buffer. It must be realized that the administration Germany.
of the buffer-free electrolyte solution may endanger the E-mail: horst.kierdorf@t-online.de
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